More than 300 million people, or 5% of the worldwide population, are living with a rare disease, defined as a disease that affects fewer than 200,000 people at any given time. Those with rare diseases are often misdiagnosed or not diagnosed at all, which makes it nearly impossible to find the right care.
Arriving at a definitive diagnosis of any given neurodegenerative condition is not always easy. Recent studies have shown that even in the hands of the best movement disorder specialists, patients diagnosed
with Parkinson’s disease who come to autopsy show no evidence of Lewy bodies and have an alternate diagnosis 30% of the time. Similar data exist for patients with multiple sclerosis, Alzheimer’s disease, and immune-mediated neuropathies. These data tell us that clinical diagnostic skills and tests cannot always accurately distinguish the varied forms of neurodegenerative diseases.
A core value at CND Life Sciences is being clinician-minded. We are founded by practicing neurologists and we are dedicated to helping clinicians care for patients facing a possible diagnosis of a neurodegenerative disease. While the biopsy procedure is straight-forward, we understand that not all neurologists have performed skin biopsies.
In CND Life Sciences’ newest case study, Dr. Todd Levine describes the case of a 64-year-old woman with a long history of multiple sclerosis. She had tried several treatments over the previous three decades with varying degrees of success and exhibited a classic relapsing-remitting disease course.
Dr. Todd Levine, CND Life Sciences’ Co-Founder and CMO, will speak at the product presentation theater at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting this month. His talk, “In-Office Cutaneous Testing for Pure Autonomic Failure and Other Synucleinopathies: Introducing the Syn-One Test™,” will be held Friday, October 15 at 3:40 pm MST.
CND Life Sciences is pleased to host an educational webinar discussing the science and utility of our Syn-One Test™, the first in-office, cutaneous diagnostic tool for Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder.
Having a core mission is foundational for any endeavor, and ours at CND Life Sciences is to advance the care of patients who face a potential diagnosis of a neurodegenerative disease. But just as important are our values–they are our guiding principles as we strive to further our mission.
CND Life Sciences continues to increase awareness and adoption of the skin-based Syn-One Test™ for Parkinson’s disease, dementia with Lewy bodies, and other synucleinopathies, now with the new “Power of Proof” campaign, which will appear across several top neurology journals and websites.